BioCardia Targets Q4 2026 Regulatory Submission for CardiAMP in Japan
Event summary
- BioCardia CEO Peter Altman to present at H.C. Wainwright conference on September 14-16, 2026.
- Company targeting Q4 2026 Shonin submission for CardiAMP in Japan, supported by PMDA Consultation Record.
- CardiAMP HF II pivotal trial actively enrolling in the U.S., with FDA meeting minutes confirming PMA potential.
- FDA confirmed meeting minutes supporting follow-on De Novo pre-submission for Helix Transendocardial Delivery Catheter.
- Heart3D Fusion Imaging platform advancing toward potential FDA 510(k) submission.
The big picture
BioCardia is advancing its CardiAMP cell therapy through critical regulatory milestones in both Japan and the U.S., while positioning its Helix and Heart3D platforms as key enablers for cardiac biotherapeutic delivery. The company's progress reflects broader industry trends toward targeted cell and gene therapies for cardiovascular diseases, with potential to expand through strategic partnerships. Success hinges on navigating regulatory pathways and demonstrating clinical efficacy in pivotal trials.
What we're watching
- Regulatory Momentum
- Whether BioCardia can secure PMDA approval in Japan by Q4 2026 and FDA PMA for CardiAMP based on CardiAMP HF II trial results.
- Technology Differentiation
- The pace at which Helix and Heart3D platforms gain regulatory clearance and expand partnering opportunities.
- Clinical Trial Execution
- How quickly CardiAMP HF II trial completes enrollment and whether it delivers statistically significant results.
Related topics